494 related articles for article (PubMed ID: 29477740)
1. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis.
Lockshin B; Balagula Y; Merola JF
J Am Acad Dermatol; 2018 Aug; 79(2):345-352. PubMed ID: 29477740
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.
Furue M; Tsuji G; Chiba T; Kadono T
Intern Med; 2017; 56(13):1613-1619. PubMed ID: 28674347
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk.
Visser MJE; Tarr G; Pretorius E
Front Immunol; 2021; 12():688861. PubMed ID: 34335591
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease.
Karbach S; Croxford AL; Oelze M; Schüler R; Minwegen D; Wegner J; Koukes L; Yogev N; Nikolaev A; Reißig S; Ullmann A; Knorr M; Waldner M; Neurath MF; Li H; Wu Z; Brochhausen C; Scheller J; Rose-John S; Piotrowski C; Bechmann I; Radsak M; Wild P; Daiber A; von Stebut E; Wenzel P; Waisman A; Münzel T
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2658-68. PubMed ID: 25341795
[TBL] [Abstract][Full Text] [Related]
5. Long-term prognosis in patients with psoriasis.
Gulliver W
Br J Dermatol; 2008 Aug; 159 Suppl 2():2-9. PubMed ID: 18700909
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis as a cardiovascular risk factor: updates and algorithmic approach.
Cozzani E; Rosa GM; Burlando M; Parodi A
G Ital Dermatol Venereol; 2018 Oct; 153(5):659-665. PubMed ID: 29683293
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis and cardiovascular disorders.
Ryan C; Menter A
G Ital Dermatol Venereol; 2012 Apr; 147(2):179-87. PubMed ID: 22481581
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A
Front Immunol; 2018; 9():1668. PubMed ID: 30150978
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
[TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular risk in systemic inflammatory diseases].
Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
[TBL] [Abstract][Full Text] [Related]
11. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
Torres T; Raposo I; Selores M
Am J Clin Dermatol; 2016 Apr; 17(2):107-12. PubMed ID: 26596991
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.
Hu SC; Lan CE
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29065479
[TBL] [Abstract][Full Text] [Related]
15. [Psoriasis and cardiovascular risk factors].
Tal R; Pavlovsky L; David M
Harefuah; 2012 Oct; 151(10):573-5, 605. PubMed ID: 23316664
[TBL] [Abstract][Full Text] [Related]
16. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
Tong Y; Peranteau AJ; Nawas Z; Tyring SK
Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
[TBL] [Abstract][Full Text] [Related]
17. Does treatment of psoriasis reduce the risk of cardiovascular disease?
Churton S; Brown L; Shin TM; Korman NJ
Drugs; 2014 Feb; 74(2):169-82. PubMed ID: 24420963
[TBL] [Abstract][Full Text] [Related]
18. Cardiometabolic Disorders in Psoriatic Disease.
Sobchak C; Eder L
Curr Rheumatol Rep; 2017 Aug; 19(10):63. PubMed ID: 28844116
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab in the treatment of psoriasis: an update.
Reszke R; Szepietowski JC
Immunotherapy; 2017 Mar; 9(3):229-238. PubMed ID: 28162025
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis and cardiovascular diseases.
Vizzardi E; Raddino R; Teli M; Gorga E; Brambilla G; Dei Cas L
Acta Cardiol; 2010 Jun; 65(3):337-40. PubMed ID: 20666273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
